Meds A-Z
Tulathromycin
Detailed information about Tulathromycin
Veterinary professional?
Add to My Pet's Meds
Choose a pet, confirm current or past, and optionally add reminder notes.
Sign in to save this medication to your pet profile.
Sign in to continueReviewed / Updated / Sources
Reviewed: Not available
Updated: February 12, 2026, 10:44 PM UTC
- FDA application profile · official_label
- FDA application profile · official_label
- Medication usage source · fda_animal_drugs
- Tulaject™ 100 · official_label
- openFDA case USA-USFDACVM-2024-US-013392 · adverse_reaction
Pet Owner Quick Guide
Start here first for the simple next-step summary.
Used for:
BRD – Tulathromycin Injection is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica , Pasteurella multocida , Histophilus somni , and Mycoplasma bovis ; and for the con...
What to watch for:
- Do not inject more than 4 mL per injection site
- For use in suckling calves, dairy calves, veal calves, and swine
- Not for use in ruminating cattle
- Not for use in Chickens or Turkeys
- Federal (USA) law restricts this drug to useby or on the order of a licensed veterinarian
- Do not inject more than 11.5 mL per injection site
- Vocalisation (1 reports)
- trouble breathing (1 reports)
- very low energy (1 reports)
When to call the vet:
- Repeated vomiting or diarrhea.
- Severe lethargy (hard to wake, very low energy).
- Collapse or fainting.
- Facial swelling or hives.
- Blood in vomit or stool.
What to ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Safety & side effects
What to watch:
- Do not inject more than 4 mL per injection site
- For use in suckling calves, dairy calves, veal calves, and swine
- Not for use in ruminating cattle
- Not for use in Chickens or Turkeys
- Federal (USA) law restricts this drug to useby or on the order of a licensed veterinarian
Most reported reactions:
- Vocalisation (1 reports)
- Trouble breathing (dyspnea) (1 reports)
- Tiredness (lethargy) (1 reports)
When to call your vet:
- Repeated vomiting or diarrhea.
- Severe lethargy (hard to wake, very low energy).
- Collapse or fainting.
- Facial swelling or hives.
Data freshness: source data appears current.
Latest refresh: Mar 21, 2026, 10:01 a.m.
- Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Mar 21, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Mar 21, 2026, 10:01 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 9, 2026, 3:13 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC
Tulathromycin
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: Not available (source)
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200742 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200774 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source
Warnings / Contraindications
Do not inject more than 4 mL per injection site. For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle. Not for use in Chickens or Turkeys. Federal (USA) law restricts this drug to useby or on the order of a licensed veterinarian. Do not inject more than 11.5 mL per injection site. For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle. Not for use in Chickens or Turkeys. Federal (USA) law restricts this drug to useby or on the order of a licensed veterinarian.
- High: Do not inject more than 4 mL per injection site. For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle. Not for use in Chickens or Turkeys. Federal (USA) law restricts this drug to useby or on the order of a licensed veterinarian. Do not inject more than 11.5 mL per injection site. For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle. Not for use in Chickens or Turkeys. Federal (USA) law restricts this drug to useby or on the order of a licensed veterinarian.
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Grouped by Body System
Most Reported Reactions
| Reaction | Body system | Cases | Species | Serious cases |
|---|---|---|---|---|
| Other | 1 | Cat | 1 | |
| Other | 1 | Dog | 1 | |
| Neurologic | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 | |
| Neurologic | 1 | Cat | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Cat | 1 |
Species coverage: Dog (12) Cat (10)
View detailed reaction table
| Reaction | Body system | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|---|
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Neurologic | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Neurologic | Cat | Serious | - | 1 | |
| Effectiveness | Dog | Non-serious | - | 1 | |
| Effectiveness | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Neurologic | Dog | Unknown | - | - | |
| Other | Cat | Unknown | - | - | |
| Other | Cat | Unknown | - | - | |
| Other | Cat | Unknown | - | - |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2024-US-013392
Documents
Owner handouts and official technical documents are grouped for faster access.
Owner handouts (0)
- No owner handouts linked yet.
Official label / PI (0)
- No official label or package insert links yet.
SPL (16)
-
Tulathromycin Injection
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/16868/Tulathromycin%20Injection
-
Tulaject™
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/16167/Tulaject%E2%84%A2
-
Tulaject™ 100
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/16145/Tulaject%E2%84%A2%20100
-
RESPIRmycin™ 25
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13855/RESPIRmycin%E2%84%A2%2025
-
RESPIRmycin™
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13217/RESPIRmycin%E2%84%A2
-
Tulieve®
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/12218/Tulieve%C2%AE
-
AROVYN™
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/12095/AROVYN%E2%84%A2
-
Increxxa™ 25
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/12055/Increxxa%E2%84%A2%2025
-
TULAVEN™ 100
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/11596/TULAVEN%E2%84%A2%20100
-
TULAVEN™ 25
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/11615/TULAVEN%E2%84%A2%2025
-
Tulissin® 100
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/11635/Tulissin%C2%AE%20100
-
Tulissin® 25
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/11633/Tulissin%C2%AE%2025
-
Draxxin® KP
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/10934/Draxxin%C2%AE%20KP
-
Increxxa™
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/10490/Increxxa%E2%84%A2
-
MACROSYN™
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/10491/MACROSYN%E2%84%A2
-
Draxxin® 25 Injectable Solution
· SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2312/Draxxin%C2%AE%2025%20Injectable%20Solution
FOI (17)
-
FOI Summary oA 200-742 Approved February 25, 2025.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/16586
-
FOI Summary oA 200-774 Approved September 10, 2024.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15846
-
FOI Summary oA 200-773 Approved September 5, 2024.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15825
-
FOI Summary oA 200-745 Approved March 21, 2023.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13658
-
FOI Summary oA 200-730 Approved November 4, 2022.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13114
-
FOI Summary oA 200-723 Approved March 23, 2022.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/12171
-
FOI Summary oA 200-715 Approved February 9, 2022.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/12047
-
FOI Summary oA 200-665 Approved February 7, 2022.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11987
-
FOI Summary oA 200-711 Approved November 1, 2021.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11506
-
FOI Summary oA 200-712 Approved November 3, 2021.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11525
-
FOI Summary oA 200-669 Approved November 15, 2021.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11545
-
FOI Summary oA 200-668 Approved November 12, 2021.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11543
-
FOI Summary oN 141-543 Approved June 1, 2021.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/10884
-
FOI Summary oA 200-666 Approved February 18, 2021.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/10432
-
FOI Summary oA 200-657 Approved February 18, 2021.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/10431
-
UCM436589.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/906
-
UCM374308.pdf
· FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/905
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/16586 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/16868/Tulathromycin%20Injection · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15846 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/16167/Tulaject%E2%84%A2 · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15825 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/16145/Tulaject%E2%84%A2%20100 · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13658 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13855/RESPIRmycin%E2%84%A2%2025 · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13114 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13217/RESPIRmycin%E2%84%A2 · document · SPL
Veterinary reference (advanced)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
- Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Mar 21, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Mar 21, 2026, 10:01 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 9, 2026, 3:13 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC
Diagnosis-code mappings are not available for this medication yet.
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
- Do not inject more than 4 mL per injection site. For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle. Not for use in Chickens or Turkeys. Federal (USA) law restricts this drug to useby or on the order of a licensed veterinarian. Do not inject more than 11.5 mL per injection site. For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle. Not for use in Chickens or Turkeys. Federal (USA) law restricts this drug to useby or on the order of a licensed veterinarian. (Contraindication, High)
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 0061-6607-02 | 0061 | - | |
| 0061-6607-03 | 0061 | - | |
| 0061-6607-04 | 0061 | - | |
| 0061-6607-05 | 0061 | - | |
| 23243-2825-1 | 23243 | - | |
| 23243-2825-2 | 23243 | - | |
| 23243-5282-1 | 23243 | - | |
| 23243-5282-2 | 23243 | - | |
| 23243-5282-5 | 23243 | - | |
| 23243-5282-6 | 23243 | - | |
| 51311-002-10 | 51311 | - | |
| 51311-002-25 | 51311 | - | |
| 51311-006-10 | 51311 | - | |
| 51311-006-25 | 51311 | - | |
| 51311-006-50 | 51311 | - | |
| 51311-006-51 | 51311 | - | |
| 54771-2155-1 | 54771 | - | |
| 54771-2155-2 | 54771 | - | |
| 54771-2155-3 | 54771 | - | |
| 54771-2155-4 | 54771 | - |
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
FOI Summary oA 200-742 Approved February 25, 2025.pdf
• FOI summary • Official
• Feb. 26, 2025
FDA FOI summary for application 200742
-
FOI Summary oA 200-774 Approved September 10, 2024.pdf
• FOI summary • Official
• Oct. 1, 2024
FDA FOI summary for application 200774
-
FOI Summary oA 200-773 Approved September 5, 2024.pdf
• FOI summary • Official
• Oct. 1, 2024
FDA FOI summary for application 200773
-
FOI Summary oA 200-745 Approved March 21, 2023.pdf
• FOI summary • Official
• April 3, 2023
FDA FOI summary for application 200745
-
FOI Summary oA 200-730 Approved November 4, 2022.pdf
• FOI summary • Official
• Dec. 1, 2022
FDA FOI summary for application 200730
-
FOI Summary oA 200-723 Approved March 23, 2022.pdf
• FOI summary • Official
• April 1, 2022
FDA FOI summary for application 200723
-
FOI Summary oA 200-715 Approved February 9, 2022.pdf
• FOI summary • Official
• March 1, 2022
FDA FOI summary for application 200715
-
FOI Summary oA 200-665 Approved February 7, 2022.pdf
• FOI summary • Official
• March 1, 2022
FDA FOI summary for application 200665
-
FOI Summary oA 200-712 Approved November 3, 2021.pdf
• FOI summary • Official
• Dec. 1, 2021
FDA FOI summary for application 200712
-
FOI Summary oA 200-711 Approved November 1, 2021.pdf
• FOI summary • Official
• Dec. 1, 2021
FDA FOI summary for application 200711
-
FOI Summary oA 200-669 Approved November 15, 2021.pdf
• FOI summary • Official
• Dec. 1, 2021
FDA FOI summary for application 200669
-
FOI Summary oA 200-668 Approved November 12, 2021.pdf
• FOI summary • Official
• Dec. 1, 2021
FDA FOI summary for application 200668
-
FOI Summary oN 141-543 Approved June 1, 2021.pdf
• FOI summary • Official
• July 1, 2021
FDA FOI summary for application 141543
-
FOI Summary oA 200-666 Approved February 18, 2021.pdf
• FOI summary • Official
• March 1, 2021
FDA FOI summary for application 200666
-
FOI Summary oA 200-657 Approved February 18, 2021.pdf
• FOI summary • Official
• March 1, 2021
FDA FOI summary for application 200657
-
UCM374308.pdf
• FOI summary • Official
• April 1, 2019
FDA FOI summary for application 141349
-
UCM436589.pdf
• FOI summary • Official
• April 1, 2019
FDA FOI summary for application 141349
Data Sources & Change Log
Every non-trivial field is expected to include provenance and update timestamps.
- contraindications: Do not inject more than 4 mL per injection site. For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle. Not for us… (Official, 2026-02-12)
- side_effects: Top reported reactions (openFDA): Coughing up blood, Cutaneous emphysema, Dyspnoea, Injection site reaction NOS, Lack of efficacy (bacteria) - NOS, Lack of eff… (Official, 2026-02-12)
- usage: For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae , Pasteurella multocida , Bordetella bronchiseptica , Haem… (Official, 2026-02-12)
- side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Tulathromycin Injection
RX
Tulathromycin
Injectable Solution
• Intramuscular, Subcutaneous
|
Hikma Pharmaceuticals USA, Inc. | ANADA 200-742 | Approved | Feb 26, 2025 |
|
Tulaject™
RX
Tulathromycin
Injectable Solution
• Intramuscular, Subcutaneous
|
Cronus Pharma Specialities India Private Ltd. | ANADA 200-774 | Approved | Oct 1, 2024 |
|
Tulaject™ 100
RX
Tulathromycin
Injectable Solution
• Subcutaneous, Intramuscular
|
Cronus Pharma Specialities India Private Ltd. | ANADA 200-773 | Approved | Oct 1, 2024 |
|
RESPIRmycin™ 25
RX
Tulathromycin
Injectable Solution
• Subcutaneous, Intramuscular
|
Parnell Technologies Pty. Ltd. | ANADA 200-745 | Approved | Apr 3, 2023 |
|
RESPIRmycin™
RX
Tulathromycin
Injectable Solution
• Subcutaneous, Intramuscular
|
Parnell Technologies Pty. Ltd. | ANADA 200-730 | Approved | Dec 1, 2022 |
|
Tulieve®
RX
Tulathromycin
Injectable Solution
• Subcutaneous, Intramuscular
|
Norbrook Laboratories, Ltd. | ANADA 200-723 | Approved | Apr 1, 2022 |
|
AROVYN™
RX
Tulathromycin
Injectable Solution
• Subcutaneous, Intramuscular
|
Intervet, Inc. | ANADA 200-715 | Approved | Mar 1, 2022 |
|
Increxxa™ 25
RX
Tulathromycin
Injectable Solution
• Subcutaneous, Intramuscular
|
Elanco US Inc. | ANADA 200-665 | Approved | Mar 1, 2022 |
|
TULAVEN™ 100
RX
Tulathromycin
Injectable Solution
• Subcutaneous, Intramuscular
|
Ceva Sante Animale | ANADA 200-711 | Approved | Dec 1, 2021 |
|
TULAVEN™ 25
RX
Tulathromycin
Injectable Solution
• Intramuscular, Subcutaneous
|
Ceva Sante Animale | ANADA 200-712 | Approved | Dec 1, 2021 |
|
Tulissin® 100
RX
Tulathromycin
Injectable Solution
• Subcutaneous, Intramuscular
|
Virbac AH, Inc. | ANADA 200-669 | Approved | Dec 1, 2021 |
|
Tulissin® 25
RX
Tulathromycin
Injectable Solution
• Subcutaneous, Intramuscular
|
Virbac AH, Inc. | ANADA 200-668 | Approved | Dec 1, 2021 |
|
Draxxin® KP
RX
Ketoprofen Tulathromycin
Injectable Solution
• Subcutaneous
|
Zoetis Inc. | NADA 141-543 | Approved | Jul 1, 2021 |
|
Increxxa™
RX
Tulathromycin
Injectable Solution
• Subcutaneous, Intramuscular
|
Elanco US Inc. | ANADA 200-666 | Approved | Mar 1, 2021 |
|
MACROSYN™
RX
Tulathromycin
Injectable Solution
• Intramuscular, Subcutaneous
|
Bimeda Animal Health Limited | ANADA 200-657 | Approved | Mar 1, 2021 |
|
Draxxin® 25 Injectable Solution
RX
Tulathromycin
Injectable Solution
• Intramuscular, Subcutaneous
|
Zoetis Inc. | NADA 141-349 | Approved | Apr 1, 2019 |
Data source: FDA Animal Drugs @ FDA (public search export).
What It's For (FDA Label Highlights)
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Composition / specifications
BRD – Tulathromycin Injection is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
IBK – Tulathromycin Injection is indicated for the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
Foot Rot – Tulathromycin Injection is indicated for the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Suckling Calves, Dairy Calves, and Veal Calves
BRD – Tulathromycin Injection is indicated for the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
Tulathromycin Injection is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22lb) body weight (BW). Do not inject more than 4 mL per injection site.
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22lb) BW. Do not inject more than 11.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
BRD- For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
IBK- For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis
Foot Rot- For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) body weight (BW). Do not inject more than 4 mL per injection site.
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
Inject subcutaneously as a single dose in the neck at a dose of 2.5 mg/kg (1 mL/22 lb BW. Do not inject more than 11.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
BRD – For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
IBK – For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
Foot Rot – For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
For the treatment of infectious bovine keratoconjunctivitis associated with Moraxella bovis.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
For the treatment of infectious bovine keratoconjunctivitis associated with Moraxella bovis.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (1mL/22 lb) body weight (BW). Do not inject more than 4 mL per injection site.
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1mL/22 lb) BW. Do not inject more than 11.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
BRD: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
IBK: For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
Foot Rot: For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg(1 mL/22 lb) body weight (BW). Do not inject more than 4 mL per injection site.
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) BW. Do not inject more than 11.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
BRD: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
IBK: For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
Foot Rot: For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) body weight (BW). Do not inject more than 4 mL per injection site.
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) BW. Do not inject more than 11.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of pyrexia associated with BRD in beef steers, beef heifers, beef calves 2 months of age and older, beef bulls, dairy bulls, and replacement dairy heifers.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg tulathromycin and 3 mg ketoprofen/kg (1.1 mL/100 lb) bodyweight.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb.) bodyweight (BW). Do not inject more than 10 mL per injection site.
For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb.) bodyweight (BW). Do not inject more than 10 mL per injection site.
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb.) BW. Do not inject more than 2.5 mL per injection site.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Official Documents (FDA)
Direct links to FDA-hosted PDFs and SPL packages (when available).
-
Summary
Beef cattle, non-lactating dairy cattle, suckling calves, dairy calves and veal calves
BRD- Tulathromycin Injection is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
IBK- Tulathromycin Injection is indicated for the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
Foot Rot- Tulathromycin Injection is indicated for the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Suckling Calves, Dairy Calves, and Veal Calves
BRD- Tulathromycin Injection is indicated for the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Swine
Tulathromycin Injection is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
- Tulathromycin Injection (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Swine- For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Suckling Calves, Dairy Calves, and Veal Calves
BRD- For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
- Tulaject™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Beef and Non-Lactating Dairy Cattle
BRD- For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
IBK- For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
Foot Rot- For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.Â
Suckling Calves, Dairy Calves, and Veal Calves
BRD- For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Swine- For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
- Tulaject™ 100 (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Swine: For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Suckling Calves, Dairy Calves, and Veal Calves: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
- RESPIRmycin™ 25 (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Beef and Non-Lactating Dairy Cattle
BRD- For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
IBK- For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
Foot Rot- For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Suckling Calves, Dairy Calves, and Veal Calves
BRD- For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Swine
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
- RESPIRmycin™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Beef and Non-Lactating Dairy Cattle: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
For the treatment of infectious bovine keratoconjunctivitis associated with Moraxella bovis.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Suckling Calves, Dairy Calves, and Veal Calves: For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Swine: For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
- Tulieve® (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Beef and Non-Lactating Dairy Cattle: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
For the treatment of infectious bovine keratoconjunctivitis associated with Moraxella bovis.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Suckling Calves, Dairy Calves, and Veal Calves: For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Swine: For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
- AROVYN™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
- Increxxa™ 25 (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Beef and Non-Lactating Dairy Cattle: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Suckling Calves, Dairy Calves, and Veal Calves: For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Swine: For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
- TULAVEN™ 100 (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Swine: For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Suckling Calves, Dairy Calves, and Veal Calves: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
- TULAVEN™ 25 (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Beef and Non-Lactating Dairy Cattle: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Suckling Calves, Dairy Calves, and Veal Calves: For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Swine: For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
- Tulissin® 100 (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Swine: For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
Suckling Calves, Dairy Calves, and Veal Calves: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
- Tulissin® 25 (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of pyrexia associated with BRD in beef steers, beef heifers, beef calves 2 months of age and older, beef bulls, dairy bulls, and replacement dairy heifers.
- Draxxin® KP (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Beef and Non-Lactating Dairy Cattle
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Suckling Calves, Dairy Calves, and Veal Calves
For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Swine
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
- Increxxa™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Beef and Non-Lactating Dairy Cattle
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Suckling Calves, Dairy Calves, and Veal Calves
For the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
Swine
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
- MACROSYN™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI UCM436589.pdf
Summary
This supplement provides for use in suckling calves, dairy calves, and veal calves for the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis. -
FOI UCM374308.pdf
Summary
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with A. pleuropneumoniae, P. multocida, and M. hyopneumoniae in groups of pigs where SRD has been diagnosed.
FDA page: Open in Animal Drugs @ FDA
Usage
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae , Pasteurella multocida , Bordetella bronchiseptica , Haemophilus parasuis , and Mycoplasma hyopneumoniae ; and for the control of SRD associated with Actinobacillus pleuropneumoniae , Pasteurella multocida , and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed. For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica , Pasteurella multocida , Histophilus somni , and Mycoplasma bovis . For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica , Pasteurella multocida , Histophilus somni , and Mycoplasma bovis , and control of pyrexia associated with BRD in beef steers, beef heifers, beef calves 2 months of age and older, beef bulls, dairy bulls, and replacement dairy heifers.
Source: FDA Animal Drugs @ FDA • Reference
Contraindications
Do not inject more than 4 mL per injection site. For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle. Not for use in Chickens or Turkeys. Federal (USA) law restricts this drug to useby or on the order of a licensed veterinarian. Do not inject more than 11.5 mL per injection site. For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle. Not for use in Chickens or Turkeys. Federal (USA) law restricts this drug to useby or on the order of a licensed veterinarian.
Top Reported Reactions (openFDA)
De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).
Showing top 5 for Neurologic.
Showing top 5 for Effectiveness.
Show more (9)
Showing top 5 for Other.
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Poodle (unspecified), Male, 16.964 kilogram • Drug: MSK, Injection, Unknown, Dose: 0.50 mL per animal • Reactions: Cutaneous emphysema, Coughing up blood, Pneumothorax • Outcome: Ongoing
- Report ID: USA-USFDACVM-2024-US-068637
- Serious AE: Yes
- Treated For AE: No
- Sex: Male
- Weight: 16.964 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Injection
- Dose: 0.50 mL per animal
Cat, Cat (unknown), Male, 10 year, 4 kilogram • Drug: MSK, Subcutaneous, Dose: 0.15 mL per animal • Reactions: Blindness, Neurological signs NOS, Vocalisation, Elevated alanine aminotransferase, Elevated aspartate aminotransferase… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2024-US-013392
- Serious AE: Yes
- Treated For AE: No
- Sex: Male
- Age: 10.00 Year
- Weight: 4.000 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Dose: 0.15 mL per animal
Cat, Domestic Shorthair, Male, 10 year, 4 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 0.15 mL per animal • Reactions: Blindness, Neurological signs NOS, Vocalisation, Elevated alanine aminotransferase, Elevated aspartate aminotransferase… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2024-US-005492
- Serious AE: Yes
- Treated For AE: No
- Sex: Male
- Age: 10.00 Year
- Weight: 4.000 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Injection
- Dose: 0.15 mL per animal
Cat, Cat (other), Unknown • Drug: MSK, Injection, Unknown, Dose: 0.50 mL per animal • Reactions: Blindness • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2022-US-050395
- Serious AE: Yes
- Treated For AE: No
- Sex: Unknown
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Injection
- Dose: 0.50 mL per animal
Dog, Great Pyrenees, Female, 19 week, 11.703 kilogram • Drug: MSK, Solution, Unknown • Reactions: Oral cavity disorder NOS • Outcome: Ongoing
- Report ID: USA-USFDACVM-2022-US-030251
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 19.00 Week
- Weight: 11.703 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Solution
Dog, Deutsche Dogge, Great Dane, Unknown, 9 month, 35.834 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 1.50 mL per animal • Reactions: Lack of efficacy (bacteria) - NOS, Overdose • Outcome: Ongoing
- Report ID: USA-USFDACVM-2022-US-005144
- Serious AE: No
- Treated For AE: No
- Sex: Unknown
- Age: 9.00 Month
- Weight: 35.834 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Injection
- Dose: 1.50 mL per animal
Cat, Domestic Mediumhair, Female, 4 year • Drug: MSK, Injection, Unknown • Reactions: Lack of efficacy - NOS • Outcome: Ongoing
- Report ID: USA-USFDACVM-2020-US-023278
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 4.00 Year
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Injection
Dog, ['Siberian Husky', 'Poodle (unspecified)'], Male, 11 week, 6.804 kilogram • Drug: MSK, Injection, Unknown • Reactions: Lack of efficacy - NOS • Outcome: Ongoing
- Report ID: USA-USFDACVM-2020-US-015293
- Serious AE: No
- Treated For AE: Yes
- Sex: Male
- Age: 11.00 Week
- Weight: 6.804 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Injection
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
Storage & Handling
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.